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Transcription factor 4 (TCF4) expression predicts
clinical outcome in RUNX1 mutated and 
translocated acute myeloid leukemia
Transcription factors play an essential role in
hematopoiesis. Aberrations in transcription factors may
contribute to the development and maintenance of
leukemia. Runt related transcription factor 1 (RUNX1,
a.k.a. AML1, CBFa2 or PEBP2aB) is a transcription factor
which belongs to the core-binding factor (CBF) family.
RUNX1 directly contacts DNA, but the binding affinity
for DNA significantly increases after dimerizing with its
cofactor, core binding factor-β (CBFβ). RUNX1 plays a
key role in definitive hematopoiesis, and disruption of
RUNX1 contributes to malignant transformation.1 In
acute myeloid leukemia (AML), RUNX1 mutations
(RUNX1mut) are frequently found and are associated with
a poor prognosis.1-3 Furthermore, more than a dozen dif-
ferent chromosomal translocations have been described
that involve either RUNX1 or its partner CBFβ. Of these,
the most common translocations are the
t(8;21)(q22;q22), leading to a fusion protein RUNX1-
RUNX1T1, and the inv(16)(p13;q22)) leading to a 
CBF-MYH11 fusion protein. These aberrations are found
in approximately 12-15% and 8-10% of adult AML
respectively.1 Interestingly, CBF translocations are associ-
ated with a favorable prognosis.1 For almost a decade,
t(8;21) (RUNX1-RUNX1T1) and inv(16) (CBFβ-MYH11)
have been incorporated as a separate AML entity with
favorable prognosis in the World Health Organization
(WHO) classification of myeloid neoplasms and acute
leukemia. In addition, in the European Leukemia Net
(ELN) recommendations of diagnosis and management of
AML they are incorporated as important markers of good
prognosis. In the recent WHO classification update in
2016, AML with a RUNX1mut has been added as a provi-
sional entity and this category of AML has also been clas-
sified in the ELN recommendations as a poor prognostic
group. The exact working mechanism via which
RUNX1mut operates has not yet been elucidated.
Previously, we found that the expression level of tran-
scription factor 4 (TCF4, also known as E2-2 and ITF2) is
an independent prognostic factor in AML, after correc-
tion for ELN risk group (2010), age and white blood cell
count. Patients with high TCF4 mRNA expression (high-
est quartile) have a worse survival and benefit more from
a more aggressive treatment approach compared to
patients with low TCF4 expression.4 In accordance, TCF4
expression significantly contributes to expression signa-
tures linked with poor AML outcome.5 TCF4 is implicat-
ed in erythroid-megakaryocytic differentiation, B- and 
T-cell development and is crucial for plasmacytoid DC
(pDC) development.6,7 In blastic plasmacytoid dendritic
cell neoplasms (BPDCN) TCF4 has been shown to be the
master regulator of the oncogenic program.7 A role for
TCF4 in malignant hematopoiesis is further indicated by
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Table 1. Multivariate Cox regression analysis.                                                                                                                       
A                                                                         Excluding TCF4                                                                                 Including TCF4
OS; Variable                                 Wald                    HR (95% CI)                P                       df              Wald                     HR (95% CI)          P
TCF4                                                                                                                                                                 1                   8.86                                   1.61                 0.003
highest 25%                                                                                                                                                                                                            (1.18 - 2.21)              
RUNX1                                                   6.29                                 1.77                        0.012                         1                   2.30                                   1.43                 0.129
mutation                                                                                 (1.13 - 2.76)                                                                                                           (0.90 - 2.28)               
WBC                                                      13.17                                2.02                                                                                                                          1.96                 0.001
>100x109/L                                                                             (1.38 - 2.95)                <0.001                       1                  12.10                          (1.34 - 2.87)               
B                                                                           Excluding TCF4                                                Including TCF4
B                                                                           Excluding TCF4                                                                                   Including TCF4
OS; Variable                                 Wald                    HR (95% CI)                P                       df              Wald                     HR (95% CI)          P
TCF4                                                                                                                                                                 1                   9.09                                   1.49                 0.003
highest 25%                                                                                                                                                                                                            (1.15 - 1.93)
t(8;21)                                                    4.13                                 0.57                        0.042                         1                   2.75                                   0.63                 0.098
present                                                                                   (0.33 - 0.98)                                                                                                           (0.37 - 1.09)               
WBC                                                      11.06                                1.81                        0.001                         1                  10.83                                  1.80                 0.001
>100x09/L                                                                               (1.28 - 2.58)                                                                                                           (1.27 - 2.56)               
C                                                                           Excluding TCF4                                                                                   Including TCF4
OS; Variable                                 Wald                    HR (95% CI)                P                       df              Wald                     HR (95% CI)          P
TCF4                                                                                                                                                                 1                   9.05                                   1.49                 0.003
highest 25%                                                                                                                                                                                                        (1.15 - 1.92)
inv(16)                                                  14.06                                0.40                       <0.001                       1                  12.85                                  0.42               <0.001
present                                                                                   (0.25 - 0.65)                                                                                                           (0.26 - 0.67)               
WBC                                                      11.20                                1.81                        0.001                         1                  10.71                                  1.80                 0.001
>100x109/L                                                                             (1.28 - 2.59)                                                                                                           (1.27 - 2.55)               
(A) Overall survival (OS); left RUNX1 status and white blood cell count (WBC) included in the model; and right TCF4 expression, RUNX1 status and WBC included in the
model. (B) OS; left t(8;21) and WBC included in the model; and right TCF4 expression, t(8;21) and WBC included in the model. (C) OS; left inv(16) and WBC included in
the model; and right TCF4 expression, inv(16) and WBC included in the model. 
the finding that mutations in TCF4 are found in AML and
myelodysplastic syndromes (MDS), albeit at low fre-
quencies.4 Furthermore, high TCF4 expression is associat-
ed with self-renewal properties8 and is downregulated
during differentiation unless progenitors obtain trans-
formed properties.8-10 
We analyzed the TCF4 expression in an independent
cohort of 436 AML patients, of which 330 cases with a
known RUNX1 status. Patients with a RUNX1mut (n=26
[7.9%]), had a significantly higher TCF4 expression while
t(8;21) patients had a significantly lower TCF4 expression
compared to patients without a CBF aberration (Figure
1A; mean 0.79 vs. -0.02, P<0.001 and -0.91 vs. -0.02,
P<0.001, respectively). Patients with an inv(16) (affecting
the CBFβ gene, which serves as a dimerization partner
for RUNX1), had a TCF4 expression comparable to
patients without a CBF aberration (Figure 1A, mean -0.20
vs. -0.02, P=0.374). Patients with RUNX1mut with a vari-
ant allele frequency (VAF) ≥40% (n=16) showed a higher
TCF4 expression compared to patients with a RUNX1
mutation with a VAF <40% (n=10; Figure 1B; mean 1.02
vs. 0.42, P=0.061). Furthermore, RUNX1mut mutations
that were more likely to alter protein function (truncating
mutations (n=17)) showed a significantly higher impact
on TCF4 expression than non-truncated RUNX1mut muta-
tions (n=9; Figure 1B; mean 1.02 vs. 0.35, P=0.024). To
corroborate these findings, we analyzed the publicly
available Vizome dataset (http://www.vizome.org/ aml/). In
484 AML patients, there were significantly more
RUNX1mut patients in the high TCF4 (highest 25%)
expressing group compared to the low TCF4 expressing
group (lowest 25%) (27.3% vs. 2.5%, P<0.0001).
Furthermore, others have shown a correlation between
RUNX1 mutations and TCF4 expression.2,3,11
In line with previous work,4 in univariate analyses,
patients in the present cohort with a high TCF4 expres-
sion (highest 25%) showed an inferior overall survival
(OS) and event free survival (EFS) compared to patients
with a low TCF4 expression (lowest 75%) (Figure 2A,
Online Supplementary Figure S1A and Online Supplementary
Table S1; 5-year OS 23% vs. 38%, P=0.001; 5-year EFS
13% vs. 31%, P<0.0001). As expected, the presence of a
RUNX1mut mutation correlated with inferior survival,
whereas a t(8;21) or inv(16) correlated with better sur-
vival (Figure 2B-D, Online Supplementary Figure S1B-D
and Online Supplementary Table S1; 5-year OS 14% vs.
38%, P=0.014, 5-year OS 49% vs. 33%, P=0.035; 5-year
OS 63% vs. 31%, P<0.0001; respectively). In addition,
we analyzed TCF4 expression and RUNX1 status is the
context of well-known prognostic factors, including
white blood cell count (WBC), cytogenetics, age and
presence of CEBPa, NPM1 or FLT3-ITD mutations in a
multivariate Cox regression model. Also here we found
that TCF4 expression is an independent prognostic fac-
tor, either divided in highest 25% and 75% lowest
expression or as continues variable, in and out of the con-
text of RUNX1 status (Online Supplementary Table S2A-D).
We did not consider t(8;21) in this context, since it has
already been incorporated in the cytogenetic risk groups.
Therefore, we performed another multivariate analyses
merely to test if the predictive effect of RUNX1mut or
t(8;21) is dependent on TCF4 expression, since both
these RUNX1 aberrations and TCF4 expression are corre-
lated and have an impact on univariate survival. A multi-
variate Cox regression analysis including WBC, RUNX1
mutational status and/or TCF4 expression (highest quar-
tile/lowest 75%) was performed. Cytogenetics, molecu-
lar markers and age were not included in this multivariate
model, because of their correlation with TCF4 expression
or RUNX1 status (Online Supplementary Table S3A). When
TCF4 expression was not taken into account, RUNX1 sta-
tus and WBC were both independent prognostic vari-
ables for OS (Table 1A; RUNX1mut hazard ratio [HR] 1.77,




Figure 1. TCF4 expression in acute myeloid leukemia (AML) patients with (A) no core binding factor (CBF) mutations (n=245), RUNX1 mutations (n=26), t(8;21)
(n=24) and inv(16) (n=35). (B) RUNX1 wild-type (n=306), RUNX1mut variant allele frequency (VAF) ≥40 (n=16), RUNX1mut  VAF <40% (n=10), truncated RUNX1mut
(n=17), non-truncated RUNX1mut (n=9). AU: arbitrary unit; ***: P<0.0001; ns: not significant.
EFS (Online Supplementary Table S3B). However, when
TCF4 expression was added to this model, WBC and
TCF4 expression showed a significant effect on OS,
while the RUNX1 mutational status lost its significance
and had a diminished HR of more than 10% (indicating
there is a direct correlation between these variables) in
both OS (Table 1A; RUNX1mut HR 1.43, 95% CI: 0.90-
2.28, P=0.129) and EFS (Online Supplementary Table S3B).
This indicates that the significance of RUNX1mut is
dependent on TCF4 expression. In contrast, when adding
RUNX1mut to an equation with TCF4 expression and
WBC, the addition of RUNX1 status had no noteworthy
impact on the significance or HR of TCF4 expression
(Online Supplementary Table S4A-B). Analyzing RUNX1
translocation in the multivariate model showed that also
the prognostic impact of t(8;21) diminished strongly
when TCF4 expression was included  (Table 1B and
Online Supplementary Table S3C), however less pro-
nounced than RUNX1mut. Again, the addition of t(8;21)
had no noteworthy impact on the significance or HR of
TCF4 expression (Online Supplementary Table S4C-D). In
contrast, the effect of the inv(16) remained significant on
OS and EFS independently of the presence of TCF4
expression (Table 1C, Online Supplementary Table S3D
and Online Supplementary Table S4E-F). This is in accor-
dance with the independency of inv(16) for TCF4 expres-
sion. 
Aberrations of RUNX1 are widely used in the clinic for
the biological and prognostic classification of AML. The
pathomechanisms explaining the different outcome of
the different RUNX1 aberrations, however, is not yet elu-
cidated. We and others show that TCF4 is highly
expressed in RUNX1mut AML,2,3,11 while there is a low
expression in t(8;21) AML patients.4,12 This corresponds
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Figure 2. Overall survival (OS) curves for acute myeloid leukemia patients with available data stratified on (A) TCF4 expression, lowest 75% (n=324), highest 25%
(n=108); (B) RUNX1 mutational status, RUNX1 wild-type (n=304), RUNX1 mutation (n=26); (C) presence (n=31) or absence of t(8;21) (n=405); (D) presence






with the poor prognosis of high TCF4 (highest 25%)
expression and RUNX1mut and the favorable prognosis of
low TCF4 expression and t(8;21) AML patients.4
Interestingly, we show in a multivariate analysis that
TCF4 expression prevails over RUNX1 status in predict-
ing outcome in AML. Possibly, RUNX1, being a transcrip-
tion factor, has a direct effect on the TCF4 promoter,
which is different between RUNX1 wild-type, RUNX1mut
and RUNX1-RUNX1T1. In primary AML, RUNX1 has
been shown to bind to the TCF4 promoter in RUNX1
wild-type and RUNX1mut cells, however there was no
AML-ETO binding on the TCF4 promoter in AML-ETO
primary cells (Online Supplementary Figure S2).13 In con-
trast, in Kasumi cells, RUNX1 did bind to the TCF4 pro-
moter.14 TCF4 has been described as one of the most
dominant factors involved in self-renewal.8-10,15 In granu-
locyte-monocyte progenitors (GMP), transduced with
various other oncogenes, TCF4 was up-regulated and
proposed to be part of the 'leukemia initiation signature.8
In addition, RUNX1 is not the only factor influencing
TCF4 expression, since only 5-10% RUNX1 mutations
are found in AML patients, while 25% of AML patients
have a high TCF4 expression. For example, in AML and
mouse models with translocations of the mixed lineage
leukemia gene (MLL) and its most common partner AF9
(MLL-AF9), TCF4 was identified as a direct transcription-
al target of MLL-AF9.15 In MLL-AF9 positive cells, TCF4
was strongly up-regulated9,10,15 and identified to be part of
the "self-renewing signature".9 Moreover, in 
MLL-rearranged AML cells, down-regulation of TCF4 or
upregulation of its natural inhibitor, prolonged the 
survival in transplantation experiments.15 The
TCF4-induced enhanced stemness may contribute to the
poor performance of AML patients with high TCF4
expression. Various oncogenes like BCL2, MYC, TCL1A
and TCL1B have been reported as downstream targets of
TCF4.7 To what extent these downstream targets are
moderators in survival and the effects of RUNX1
mutations remains to be studied.
In conclusion, we found a correlation between TCF4
expression and RUNX1 aberrations, TCF4 being upregu-
lated in RUNX1mut, and downregulated in RUNX1 translo-
cated AML (t(8;21)). TCF4 expression appeared to medi-
ate the prognostic outcome of RUNX1 aberrations. This
indicates that TCF4 might be an important downstream
target of RUNX1. Studies to identify the biological mech-
anism are warranted. 
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